Categories: Wire Stories

Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer

CRANBURY, N.J. & SHANGHAI–(BUSINESS WIRE)–Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0176, an orally bioavailable chimeric degrader molecule designed to target Androgen Receptor (AR) protein with high potency and selectivity.

�The initiation of this study marks the second program from our chimeric degrader portfolio to enter the clinic in China, after the initiation of AC0176 Phase 1 study in the US and the IND clearance by the China National Medical Products Administration (NMPA) last year,” said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. “Prostate cancer is one of the most common cancers among men in China, and the increase in its incidence and death ranks highest in China. We look forward to accelerating the development of AC0176 globally to bring transformative medicines to patients worldwide.”

The Phase 1 study in China will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0176 treatment in Chinese patients with metastatic Castration Resistant Prostate Cancer (mCRPC). Additional information on this clinical trial can be found on www.clinicaltrials.gov (NCT05673109).

About AC0176

AC0176 is an investigational orally bioavailable, chimeric degrader of androgen receptor (AR) for the potential treatment of prostate cancers. AR is a hormonal transcription factor, and plays important roles during prostate cancer onset and progression. In preclinical studies, AC0176 has demonstrated potent and selective AR protein degradation with broad coverage of AR mutants, favorable pharmacological properties, as well as promising anti-tumor activities in animal models.

About Accutar Biotechnology, Inc.

Accutar is a clinical stage biotech company focused on AI-empowered drug discovery, and its application to the discovery and development of clinically differentiated medicines.

Be transformative. For patients.

To learn more about Accutar, please visit us at www.accutarbio.com.

Contacts

jiaqiren@accutarbio.com

Alex

Recent Posts

Singapore – A Trusted Global Supply Chain Management Hub

SINGAPORE - Media OutReach Newswire - 8 November 2024 - Singapore is strengthening its position…

44 mins ago

OPPO Celebrates Global Photography Talent at Paris Photo Fair under the theme of “Dear Life”

PARIS, FRANCE - Media OutReach Newswire – 8 November 2024 - This year, OPPO once…

1 hour ago

ICONSIAM Showcases Thai Culture with “ICONSIAM THAICONIC LOY KRATHONG” Festival, Strengthening Thailand’s Global Standing

This year’s Loy Krathong event at ICONSIAM celebrates Thai cultural heritage, promotes sustainability, and shines…

1 hour ago

KBTG Vietnam and Techsauce Propel Techsauce Global Summit 2024 in Vietnam – Accelerating ASEAN’s Digital Economy

HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 8 November 2024 - KBTG…

2 hours ago

Prince Holding Group’s Chairman Chen Zhi Named Visionary Philanthropist of the Year for Impactful Initiatives in Cambodia

PHNOM PENH, CAMBODIA - Media OutReach Newswire - 8 November 2024 - Neak Oknha Chen…

3 hours ago

Telosin X Debuts in Singapore at The Mineral Boutique: Revolutionizing At-Home Skincare

SINGAPORE - Media OutReach Newswire - 8 November 2024 – Singapore's beauty enthusiasts have a…

4 hours ago